Treatment duration of complicated urinary tract infections by extended-spectrum beta-lactamases producing enterobacterales
Open Access
- 19 October 2020
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (10) , e0237365
Abstract
Urinary tract infections caused by extended-spectrum beta-lactamase producing Enterobacterales (ESBL-EB) are a problem increasing in our clinical practice. The aim of this study was to evaluate the clinical outcome in patients who received short (≤ 7 days) versus long courses (>7 days) of antimicrobial therapy for complicated ESBL-EB urinary tract infections. This is a retrospective and observational study. Positive urine cultures for ESBL-EB in our hospital between March 2015 and July 2017 were identified. Patients with complicated urinary tract infection were included. Differences between treatment groups (7 days or less vs more than 7 days) were analyzed according to baseline characteristics and severity of clinical presentation. Primary outcome was all cause 30-day mortality. Secondary outcome was a combined item of all cause mortality and reinfection by the same enterobacteria at 30 days. 273 urine cultures were positive for ESBL-EB during the study period. 75 episodes were included, 40 in the long treatment group and 35 in the short treatment group. Mean treatment duration in short and long treatment groups was 6,1 and 13,8 days respectively. Mortality at 30 days was 5,7% in the short treatment group and 5% in the long treatment group without significant differences (P = 0,8). Mortality or reinfection by the same ESBL-EB at 30 days was 8,6% in the short treatment group and 10% in the long treatment group, without significant differences (P = 0,8). Short courses of antimicrobial treatment seems to be effective as treatment of complicated urinary tract infections by ESBL-EB.Keywords
Funding Information
- No funding
This publication has 14 references indexed in Scilit:
- Shortened Courses of Antibiotics for Bacterial Infections: A Systematic Review of Randomized Controlled TrialsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2018
- Shorter Versus Longer Courses of Antibiotics for Infection in Hospitalized Patients: A Systematic Review and Meta‐AnalysisJournal of Hospital Medicine, 2018
- Treatment duration of febrile urinary tract infection: a pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and womenBMC Medicine, 2017
- Is 5 days of oral fluoroquinolone enough for acute uncomplicated pyelonephritis? The DTP randomized trialEuropean Journal of Clinical Microbiology & Infectious Diseases, 2017
- Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infectionsInternational Journal of Antimicrobial Agents, 2016
- Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trialThe Lancet, 2012
- International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious DiseasesClinical Infectious Diseases, 2011
- Carbapenem Versus Fosfomycin Tromethanol in the Treatment of Extended-Spectrum Beta-Lactamase-ProducingEscherichia Coli-Related Complicated Lower Urinary Tract InfectionJournal of Chemotherapy, 2010
- Ertapenem administered as outpatient parenteral antibiotic therapy for urinary tract infections caused by extended-spectrum- -lactamase-producing Gram-negative organismsJournal of Antimicrobial Chemotherapy, 2010
- A Double-Blind, Randomized Comparison of Levofloxacin 750 mg Once-Daily for Five Days With Ciprofloxacin 400/500 mg Twice-Daily for 10 Days for the Treatment of Complicated Urinary Tract Infections and Acute PyelonephritisUrology, 2008